Breaking News Instant updates and real-time market news.

KMPH

KemPharm

$3.20

-0.1 (-3.03%)

07:43
08/08/17
08/08
07:43
08/08/17
07:43

KemPharm publishes data on intranasal abuse of hydrocodone combination products

KemPharm announced the publication of the results from a study conducted by Inflexxion evaluating the patterns of abuse and how immediate-release hydrocodone acetaminophen combination products are administrated in the peer-reviewed journal Pharmacoepidemiology & Drug Safety. Titled "Patterns of Abuse and Routes of Administration for Immediate-Release Hydrocodone Combination Products," the peer reviewed manuscript examined prevalence of abuse of immediate-release hydrocodone combination products as compared to other classes of opioids. While prescriptions for hydrocodone combination products have recently decreased, they remain the most widely prescribed opioid products in the United States and are subject to frequent abuse among adults and adolescents. Few data existed to understand the contribution of IR products to the problem of prescription opioid abuse. This epidemiological study sought to better understand abuse patterns for IR hydrocodone combination products among adult and adolescent substance abusers. "Our findings suggest that frequently prescribed opioids, such as hydrocodone IR combination products, may contribute substantially to the overall problem of prescription opioid abuse," stated Travis Mickle, Ph.D., president and CEO of KemPharm and co-author. "The data from this study of the epidemiology of abuse of opioids in the United States confirm a prevalence of intranasal abuse of IR hydrocodone combination products among about 23% of adults and 43% of adolescents assessed for substance abuse treatment in the sampled from the Addiction Severity Index - Multimedia Version/ Comprehensive Health Assessment for Teens database. Considering that hydrocodone is the most widely prescribed opioid in the US, these figures translate into a large absolute number of individuals abusing these products intranasally. KemPharm believes this represents a significant public health risk that requires a multimodal mitigation approach, including abuse deterrent technologies."

  • 09

    Aug

  • 10

    Aug

KMPH KemPharm
$3.20

-0.1 (-3.03%)

12/07/16
OPCO
12/07/16
INITIATION
Target $13
OPCO
Outperform
KemPharm assumed with an Outperform at Oppenheimer
Oppenheimer analyst Derek Archila assumed coverage of KemPharm with an Outperform rating and raised his price target for the shares to $13 from $11. The analyst believes "multiple clinical catalysts" from the company's late-stage pipeline will create value over the next 12-18 months.
12/20/16
ADAM
12/20/16
INITIATION
Target $9
ADAM
Buy
KemPharm assumed with a Buy at Canaccord
Canaccord analyst Dewy Steadman assumed KemPharm with a Buy and $9 price target citing its drug development programs for attention deficit hyperactivity disorder, pain, and central nervous disorders.
06/28/17
ROTH
06/28/17
INITIATION
Target $8
ROTH
KemPharm initiated with a Buy at Roth Capital
Roth Capital analyst Scott Henry started KemPharm with a Buy rating and $8 price target, citing the potential for the company's lead compound as a next-generation ADHD treatment. KP415, which "appears approvable with advantages," could drive KemPharm to profitability while its pain pipeline could add further value, Henry tells investors.

TODAY'S FREE FLY STORIES

NKE

Nike

$73.94

-0.785 (-1.05%)

07:37
06/22/18
06/22
07:37
06/22/18
07:37
Downgrade
Nike rating change  »

Nike downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

AYX

Alteryx

$38.63

-1.21 (-3.04%)

07:36
06/22/18
06/22
07:36
06/22/18
07:36
Initiation
Alteryx initiated  »

Alteryx initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALBO

Albireo Pharma

$36.05

1.05 (3.00%)

07:36
06/22/18
06/22
07:36
06/22/18
07:36
Conference/Events
Albireo Pharma management to meet with Needham »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

INTC

Intel

$52.19

-1.27 (-2.38%)

, JPM

JPMorgan

$107.52

-0.04 (-0.04%)

07:35
06/22/18
06/22
07:35
06/22/18
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

INTC

Intel

$52.19

-1.27 (-2.38%)

JPM

JPMorgan

$107.52

-0.04 (-0.04%)

MS

Morgan Stanley

$49.78

-0.095 (-0.19%)

PG

Procter & Gamble

$76.44

0.59 (0.78%)

LUV

Southwest

$53.15

1.16 (2.23%)

PAGS

PagSeguro Digital

$29.42

0.91 (3.19%)

COTY

Coty

$14.48

0.03 (0.21%)

HBI

Hanesbrands

$22.04

0.615 (2.87%)

SYK

Stryker

$169.81

0.21 (0.12%)

ECA

Encana

$12.19

-0.235 (-1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

  • 13

    Jul

  • 24

    Jul

  • 26

    Jul

  • 12

    Oct

  • 22

    Jun

SRPT

Sarepta

$149.57

-4.12 (-2.68%)

07:34
06/22/18
06/22
07:34
06/22/18
07:34
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBIO

iBio

$0.95

-0.12 (-11.22%)

07:33
06/22/18
06/22
07:33
06/22/18
07:33
Syndicate
iBio raises $16M in a public offering »

The securities offered by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMG

Chipotle

$462.87

-2.66 (-0.57%)

07:33
06/22/18
06/22
07:33
06/22/18
07:33
Periodicals
Chipotle will test new menu items, strategy, NY Times reports »

Chipotle is adding five…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 26

    Jul

ABBV

AbbVie

$95.55

-2.72 (-2.77%)

07:33
06/22/18
06/22
07:33
06/22/18
07:33
Recommendations
AbbVie analyst commentary  »

AbbVie most exposed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEA

Lear

$198.83

-2.565 (-1.27%)

07:32
06/22/18
06/22
07:32
06/22/18
07:32
Conference/Events
Lear to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

QCOM

Qualcomm

$58.76

-0.03 (-0.05%)

, NXPI

NXP Semiconductors

$112.55

-0.42 (-0.37%)

07:31
06/22/18
06/22
07:31
06/22/18
07:31
Hot Stocks
Qualcomm extends cash offer for NXP Semiconductors to June 29 »

Qualcomm (QCOM) announced…

QCOM

Qualcomm

$58.76

-0.03 (-0.05%)

NXPI

NXP Semiconductors

$112.55

-0.42 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 10

    Jul

  • 12

    Jul

FOXA

21st Century Fox

$48.34

0.24 (0.50%)

, RIG

Transocean

$11.94

-0.575 (-4.60%)

07:30
06/22/18
06/22
07:30
06/22/18
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

FOXA

21st Century Fox

$48.34

0.24 (0.50%)

RIG

Transocean

$11.94

-0.575 (-4.60%)

CSX

CSX

$64.06

-0.81 (-1.25%)

Z

Zillow

$61.83

-2.84 (-4.39%)

KMB

Kimberly-Clark

$100.15

-1.51 (-1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 26

    Aug

WSC

Williams Scotsman

$12.10

-0.3 (-2.42%)

07:30
06/22/18
06/22
07:30
06/22/18
07:30
Hot Stocks
Breaking Hot Stocks news story on Williams Scotsman »

WillScot Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SENS

Senseonics

$4.96

0.1 (2.06%)

07:29
06/22/18
06/22
07:29
06/22/18
07:29
Recommendations
Senseonics analyst commentary  »

Senseonics FDA approval…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

CAKE

Cheesecake Factory

$59.87

2.13 (3.69%)

07:28
06/22/18
06/22
07:28
06/22/18
07:28
Downgrade
Cheesecake Factory rating change  »

Cheesecake Factory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WSC

Williams Scotsman

$12.10

-0.3 (-2.42%)

07:26
06/22/18
06/22
07:26
06/22/18
07:26
Conference/Events
Williams Scotsman to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SLNO

Soleno Therapeutics

$2.34

-0.02 (-0.85%)

07:26
06/22/18
06/22
07:26
06/22/18
07:26
Initiation
Soleno Therapeutics initiated  »

Soleno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTD

Trade Desk

$91.53

-1.84 (-1.97%)

07:26
06/22/18
06/22
07:26
06/22/18
07:26
Recommendations
Trade Desk analyst commentary  »

Trade Desk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRTX

Heron Therapeutics

$40.00

9.3 (30.29%)

07:25
06/22/18
06/22
07:25
06/22/18
07:25
Recommendations
Heron Therapeutics analyst commentary  »

Heron Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

KLAC

KLA-Tencor

$110.31

0.54 (0.49%)

07:24
06/22/18
06/22
07:24
06/22/18
07:24
Downgrade
KLA-Tencor rating change  »

KLA-Tencor downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHT

Red Hat

$165.62

-3.64 (-2.15%)

07:24
06/22/18
06/22
07:24
06/22/18
07:24
Recommendations
Red Hat analyst commentary  »

Red Hat price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

CSCO

Cisco

$43.17

-0.58 (-1.33%)

07:24
06/22/18
06/22
07:24
06/22/18
07:24
Recommendations
Cisco analyst commentary  »

Cisco selloff brings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 12

    Jul

TNDM

TNDM

, DXCM

DexCom

$99.72

-0.88 (-0.87%)

07:23
06/22/18
06/22
07:23
06/22/18
07:23
Recommendations
TNDM, DexCom analyst commentary  »

Tandem Diabetes'…

TNDM

TNDM

DXCM

DexCom

$99.72

-0.88 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 25

    Jun

DRI

Darden

$107.07

13.8 (14.80%)

07:22
06/22/18
06/22
07:22
06/22/18
07:22
Recommendations
Darden analyst commentary  »

Darden price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 16

    Jul

  • 17

    Jul

VSLR

Vivint Solar

$5.00

-0.05 (-0.99%)

07:20
06/22/18
06/22
07:20
06/22/18
07:20
Upgrade
Vivint Solar rating change  »

Vivint Solar upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ES

Eversource

$55.70

-0.1 (-0.18%)

, CTWS

Connecticut Water

$66.53

0.28 (0.42%)

07:20
06/22/18
06/22
07:20
06/22/18
07:20
Upgrade
Eversource, Connecticut Water rating change  »

Eversource upgraded to…

ES

Eversource

$55.70

-0.1 (-0.18%)

CTWS

Connecticut Water

$66.53

0.28 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.